UBS Group
PTLA

UBS Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

UBS Group’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-39,000
Closed -$702K – 8821
2020
Q2 		$702K Hold
39,000
– – ﹤0.01% 3849
2020
Q1 		$278K Buy
+39,000
New +$487K ﹤0.01% 4459

UBS Group's PTLA Position: Q3 2020 in Review

UBS Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 13,084 shares — an estimated $236K sold.

UBS Group first reported a position in PTLA in Q4 2014 and held it in 23 quarters. The position peaked at $6.54M in Q4 2018. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • UBS Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • UBS Group sold 13,084 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $236K.
  • UBS Group first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 23 quarters.
  • UBS Group's Portola Pharmaceuticals, Inc. position peaked at $6.54M in Q4 2018.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.